[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"impaired-fasting-glucose-ifg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:impaired-fasting-glucose-ifg":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,72,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639487","growth-hormone-resistance-of-beta-cells-100639487",false,"NCT07581860","Growth Hormone Resistance of Beta-cells","Growth Hormone Resistance of Beta-cells in People With Impaired Fasting Glucose vs Impaired Glucose Tolerance","GHRB-C","Inclusion Criteria:\n\n* body mass index \\>18.5kg\u002Fm2 and \\\u003C45.9kg\u002Fm2\n* impaired fasting glucose \\>\u002F= 100mg\u002FdL, \\\u003C\u002F= 126mg\u002FdL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg\u002FdL at two-hours)\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant during the study, or breastfeeding\n* current diagnosis or history of type 1 or type 2 diabetes\n* use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* history of bariatric surgery\n* known, uncontrolled hypothyroidism\n* history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* current cancer or cancer that has been in remission less than 5 years\n* first degree relative with type 1 diabetes\n* evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* greater than 3% weight loss within three months of screening or engaged in regular (\\>\u002F= 3 days per week), continuous moderate- or high-intensity exercise of \\>\u002F= 30 min duration\n* mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent","ALL","18 Years","59 Years",{"count":21,"type":22},10,"ESTIMATED","OBSERVATIONAL","The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[26,27,28,29],"Healthy","Obesity & Overweight","Impaired Fasting Glucose (IFG)","Impaired Glucose Tolerance (Prediabetes)","NOT_YET_RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-12","ACTUAL",{"date":36,"type":22},"2026-08-01",{"date":38,"type":22},"2030-09-01",{"name":40,"class":41},"University of Missouri-Columbia","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100613224","effect-of-a-food-supplement-on-glycemic-parameters-in-patients-with-impaired-glucose-metabolism-100613224","NCT07263802","Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism","Evaluation of the Efficacy of GlycoDual on Postprandial Glycemic Control and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism: a Randomized, Controlled, Double-blind Study","Inclusion Criteria:\n\n* body mass index (BMI) 25.0-29.9 kg\u002Fm2\n* FPG levels between 100 and 125 mg\u002Fdl \\[IFG diagnosed after Oral Glucose Tolerance Test (OGTT)\\]\n* HOMA-IR \\> 2.5\n* subjects able to understand the informed consent and sign it before enrollment in the study\n\nExclusion Criteria:\n\n* personal history of cardiovascular disease or equivalent risk factors\n* obesity (BMI ≥ 30 kg\u002Fm²)\n* taking hypoglycemic drugs or supplements that affect glycemic metabolism\n* diabetes mellitus or IGT\n* pregnancy or breastfeeding\n* known thyroid, liver, kidney or muscle diseases\n* any medical or surgical condition that makes patient compliance with the study protocol complex or inconsistent\n* any known allergy or hypersensitivity to one or more components of the food supplement","35 Years","70 Years",{"count":53,"type":22},90,"INTERVENTIONAL",[56],"NA","The primary objective will be to evaluate the efficacy of GlycoDual in reducing fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) levels compared to placebo after 90 days of treatment.\n\nSecondary objectives are to estimate:\n\n* the change of insulin sensitivity (HOMA-IR)\n* the change of uricemia after 90 days of supplementation compared to placebo.\n\nSafety objectives: Collection of the adverse events not related, related or possibly related to the study products.",[28,29],[60,61,62],"dysglycemia","Gymnema sylvestre","Zinc bisglycinate","2025-11-23",{"date":65,"type":34},"2025-12-04",{"date":67,"type":22},"2025-12-01",{"date":69,"type":22},"2026-02-28",{"name":71,"class":41},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100589501","berbevis-dose-finding-study-in-subjects-with-impaired-fasting-glucose-100589501","NCT06955234","Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose","Berbevis Project: Multitarget Dose-finding Study","BERBEVIS-DFG-0","Inclusion Criteria:\n\n* fasting blood glucose between 100 and 126 mg\u002Fdl\n* BMI between 25 and 35 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Fasting blood glucose below 100 mg\u002Fdl\n* BMI \\\u003C 25 or \\> 35 kg\u002Fm\\^2",{"count":53,"type":22},[56],"Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg\u002FdL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.",[28],{"date":85,"type":34},"2025-11-25",{"date":87,"type":22},"2026-06-15",{"date":89,"type":22},"2026-09-15",{"name":91,"class":41},"Azienda di Servizi alla Persona di Pavia",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":54,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100283455","pre-diabetes-in-subject-with-impaired-fasting-glucose-ifg-and-impaired-glucose-tolerance-igt-100283455","NCT02969798","Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","Inclusion Criteria:\n\n* NGT subjects will serve as controls and will be matched in age, gender, ethnicity, and BMI to IGT and IFG subjects\n\n  1. Male or female subjects between the ages of 18 and 65 years of age, inclusive, at Screening.\n  2. FPG \\\u003C 100 mg\u002Fdl and 2-h PG \\\u003C 140 mg\u002Fdl\n  3. BMI = 24-40 kg\u002Fm2;\n  4. Stable body weight (±4lbs) over the preceding 3 months\n  5. Subjects with no evidence of major organ system disease as determined by physical exam, history, and screening laboratory data\n  6. Females of childbearing potential with a negative pregnancy test at Screening and Treatment visits, using one of the following forms of contraception for the duration of participation in the study (i.e., until Follow-up 7-14 days post last dose):\n\n     * Oral contraceptive\n     * Injectable progesterone\n     * Subdermal implant\n     * Spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository\n     * Diaphragm with spermicide\n     * Copper or hormonal containing IUD\n     * Sterile male partner vasectomized \\> 6 month pre-dosing.\n  7. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.\n  8. Subjects must be willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures.\n\nExclusion Criteria:\n\n1. Recent (i.e., within three (3) months prior to Screening) evidence or medical history of unstable concurrent disease such as: documented evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunological, or clinically significant neurological disease.\n2. Subjects with a family history of diabetes in a first degree relative\n3. BMI of less than 24 or greater than 40 kg\u002Fm2\n4. Unstable body weight (change of greater than ±4lbs over the preceding 3 months\n5. Subjects participating in an excessively heavy exercise program\n6. Subject with a feeding\u002Fsleeping schedule different from a daytime feeding\u002Fnight time sleeping schedule\n7. Subjects taking medications known to alter glucose metabolism (with the exception of metformin and\u002For pioglitazone) or which effect brain neurosynaptic function are excluded.\n8. Subjects with evidence of major organ system disease as determined by physical exam, history, and screening laboratory data\n9. Pregnant subjects or subjects unwilling to use birth control during their study enrollment\n10. Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to Screening.\n11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study\n12. Subjects with hematuria will be excluded.\n13. Subjects with evidence or prior history of heart failure will be excluded\n14. Subjects with family history of pancreatic, bladder, and breast cancer will be excluded.\n15. Subjects with history of pancreatitis will be excluded.\n16. Subjects with eGFR \\\u003C 60 ±5 ml\u002Fmin.1.73m2 will be excluded.\n17. Subjects with elevated serum creatinine (\\>1.5 mg\u002Fdl males\u002F1.4 mg\u002Fdl females) will be excluded.\n18. Subjects with a history of orthostatic hypotension (\\>15\u002F10 mmHg) will be excluded.\n19. Subjects with liver enzymes (ALT, AST) \\>3-fold above upper normal limit will be excluded.\n20. Subjects with a history of hypersensitivity to pioglitazone, dapagliflozin, or Saxagliptin will be excluded.",true,"65 Years",{"count":102,"type":22},700,[56],"HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.",[106,107,28],"Diabetes Mellitus, Type 2","Impaired Glucose Tolerance (IGT)","RECRUITING","2025-08-25",{"date":111,"type":34},"2025-08-27",{"date":113,"type":34},"2014-01-01",{"date":115,"type":22},"2027-07",{"name":117,"class":41},"The University of Texas Health Science Center at San Antonio"]